Stock of the Day

May 30, 2023

Zimmer Biomet (ZBH)

$101.77
+$1.75 (+1.7%)
Market Cap: $19.81B

About Zimmer Biomet

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Zimmer Biomet Bull Case

Here are some ways that investors could benefit from investing in Zimmer Biomet Holdings, Inc.:

  • The current stock price is around $99.14, which is near its 50-day moving average, indicating potential stability in the short term.
  • Zimmer Biomet Holdings, Inc. reported a strong quarterly earnings performance, with earnings per share exceeding estimates, showcasing effective management and operational efficiency.
  • The company has demonstrated a year-over-year revenue growth of 7.0%, indicating a positive trend in sales and market demand for its medical products.
  • With a market capitalization of approximately $19.64 billion, Zimmer Biomet Holdings, Inc. is positioned as a significant player in the medical technology sector, which can attract institutional investors.
  • The firm has a relatively low debt-to-equity ratio of 0.54, suggesting a conservative approach to leverage and financial stability, which can be appealing to risk-averse investors.

Zimmer Biomet Bear Case

Investors should be bearish about investing in Zimmer Biomet Holdings, Inc. for these reasons:

  • The price-to-earnings ratio of 24.12 may indicate that the stock is overvalued compared to its earnings, which could deter value-focused investors.
  • Analysts have mixed ratings on the stock, with a consensus rating of "Hold," suggesting uncertainty about its future performance.
  • The PEG ratio of 2.28 indicates that the stock's price may not be justified by its earnings growth rate, which could signal potential overvaluation.
  • Recent target price adjustments by analysts have shown a downward trend, with some firms reducing their price targets, indicating a lack of confidence in short-term price appreciation.
  • The company has a quick ratio of 0.96, which is below 1, suggesting potential liquidity issues that could affect its ability to meet short-term obligations.
← Previous Stock of the DayNext Stock of the Day →

Recent News